The cohort 2 rock stars are still going strong. To quote slide 14 "Several patients with primary abiraterone resistance remain on study >46 weeks." This is great news! Zenith changed the format of their graph, so it is hard to tell who is cohort 1, 2, 3, 4 etc, with the exception of the one cohort 1 patient we already know went past 40 weeks and the 3 rock star cohort 2 patients. I also had a hard time interpreting their PSA graph slide 13, but still seems that the rock star patients have their PSA flatlined.

It also appears that they are now expanding into patients who have had progression on enzalutamide alone (enzlutamide resistance), who will now receive enzalutamide + ZEN-3694. Their combo trial started with just those experience progression on abiraterone, who were then put on enzalutamide + ZEN-3694.

Lots of good stuff "planned" for 2018/2019 on slide 15. All but the Phase 2 in #2 are listed in the 2018 part of the timeline. That sounds extremely optimistic, but we'll just have to wait and see.

1) Phase 1b/2a mCRPC trial with ZEN-3694/abiraterone combo

2) Phase 2 mCRPC trial with ZEN-3694/enzalutamide combo 

3) Phase 1b/2a: ZEN-3694 + PARPi in HRD+/ HRD- patients (breast, CRPC, ovarian), DE and DC. I did not know what all of these acronyms mean, but this helps. I still don't know what DE and DC are.

4) Ph 1b/2a : ZEN-3694 +fulvestrant in ER+ breast cancer, patients progressing on CDK 4/6 inh./ER modulator

5) Phase 1B/2a: ZEN-3694 + PD1/PD-L1 Mab in Renal/Melanoma/HNSCC/NSCLC/Bladder, others, patients progressing on PD1/PD-L1 Mab 

Keep up the good work Zenith. Fingers crossed!

BDAZ